<SEC-DOCUMENT>0000950170-23-010120.txt : 20230328
<SEC-HEADER>0000950170-23-010120.hdr.sgml : 20230328
<ACCEPTANCE-DATETIME>20230328080024
ACCESSION NUMBER:		0000950170-23-010120
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20230328
FILED AS OF DATE:		20230328
DATE AS OF CHANGE:		20230328

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Silence Therapeutics plc
		CENTRAL INDEX KEY:			0001479615
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39487
		FILM NUMBER:		23766218

	BUSINESS ADDRESS:	
		STREET 1:		72 HAMMERSMITH ROAD
		CITY:			LONDON
		STATE:			X0
		ZIP:			W14 8TH
		BUSINESS PHONE:		44-0-20-3457 6900

	MAIL ADDRESS:	
		STREET 1:		72 HAMMERSMITH ROAD
		CITY:			LONDON
		STATE:			X0
		ZIP:			W14 8TH
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sln_6-k_march_updates_3.htm
<DESCRIPTION>6-K
<TEXT>
<html>
 <head>
  <title>6-K</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="border-top:2pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Washington, D.C. 20549</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM 6-K</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">REPORT OF FOREIGN PRIVATE ISSUER</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">PURSUANT TO RULE 13a-16 OR 15d-16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For the Month of March 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Commission File Number: 001-39487</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Silence Therapeutics plc</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact Name of Registrant as Specified in Its Charter)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">72 Hammersmith Road</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">London W14 8TH</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">United Kingdom</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of principal executive offices)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="border-top:1pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Form 20-F </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0fd;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">           Form 40-F </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Wingdings&quot;, serif;min-width:fit-content;">&#xf0a8;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="border-top:2pt solid rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid rgba(0,0,0,1);text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Filed as Exhibits 99.1 and 99.2 to this Report on Form 6-K are two press releases of Silence Therapeutics plc, dated March 28, 2023.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EXHIBIT INDEX</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9.476%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:89.519%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit<br>No.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</font></p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</font><font style="white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></font><font style=""></font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press release, dated March 28, 2023, &#x201c;</font><a href="sln-ex99_1.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development</font></a><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.2</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Press release, dated March 28, 2023, &#x201c;</font><a href="sln-ex99_2.htm"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Silence Therapeutics to Buyback siRNA Complement Assets</font></a><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURE</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.498%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:6.004%;"></td>
    <td style="width:40.502%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Silence Therapeutics plc</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.007in;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Craig Tooman</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Craig Tooman</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date: March 28, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>sln-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img248120592_0.jpg" alt="img248120592_0.jpg" style="width:168px;height:63px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development</font><font style="color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">  </font></p>
  <div style="margin-left:3.333%;text-indent:0.0%;display:flex;margin-top:8.5pt;justify-content:center;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">-</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Dr. Romano will succeed Dr. Giles Campion, CMO and Head of R&amp;D, following his retirement by year-end</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.463%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.463%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">28 March 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">LONDON, Silence Therapeutics plc, Nasdaq: SLN (&#x201c;Silence&#x201d; or &#x201c;the Company&#x201d;), an experienced and innovative biotechnology company committed to transforming people&#x2019;s lives by silencing diseases through precision engineered medicines, today announced the appointment of Steven Romano, MD, as incoming</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Chief Medical Officer and Head of Research and Development. Dr. Romano will join Silence on April 1, 2023, and work alongside Giles Campion, MD, current CMO and Head of R&amp;D at Silence, to ensure an efficient and smooth transition for Dr. Campion&#x2019;s retirement by year-end.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Dr. Romano has served as non-executive director of the Silence Board since July 2019 following the Company&#x2019;s siRNA collaboration with Mallinckrodt plc for complement-mediated diseases. Since then, Dr. Romano has played a key role overseeing the company&#x2019;s complement portfolio. In a press release issued this morning, Silence announced that it was buying back two of its siRNA assets from Mallinckrodt.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;Giles has been instrumental in leading our R&amp;D efforts to get Silence to where it is today &#x2013; a clinical stage company advancing multiple programs &#x2013; and we are grateful for his continued dedication to the company,&#x201d; said Craig Tooman, President and CEO of Silence. &#x201c;We are very pleased to welcome Steven Romano to our executive team in this crucial role as we enter the next chapter of innovation and growth at Silence. His extensive experience overseeing research and development, regulatory and medical affairs make him the ideal leader to advance our clinical activities and pursue new opportunities to maximize our mRNAi GOLD&#153; platform technology.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;Being a member of the Silence Board since July 2019, I&#x2019;ve developed a deep understanding and appreciation for the company&#x2019;s siRNA platform technology to address a broad range of genetic diseases,&#x201d; said Steven Romano, MD. &#x201c;I&#x2019;m honored to assume the leadership of Silence&#x2019;s R&amp;D organization and look forward to building on this strong momentum to help bring transformative medicines to people around the world.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Dr. Romano is also a board-certified psychiatrist with more than 25 years of experience in the pharmaceutical industry, including 16 years at Pfizer.</font><font style="background-color:rgba(0,0,0,0);color:rgba(44,44,44,1);white-space:pre-wrap;font-weight:normal;font-size:13.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Most recently, he served as executive vice president and chief scientific officer at Mallinckrodt and was responsible for research and development, medical affairs, health economics and outcomes research, safety, pharmacovigilance and regulatory affairs functions. At Pfizer, Dr. Romano served in a series of senior roles, including Senior Vice President, Head, Global Medicines Development, Global Innovative Pharmaceuticals Business. Before Pfizer, he spent four years at Eli Lilly performing clinical research. Dr. Romano received his bachelor&#x2019;s degree in biology from Washington University in St. Louis and his medical degree from the University of Missouri-Columbia. He completed his residency and fellowship at New York Hospital-Cornell Medical Center, where he then served on the medical school faculty for six years.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img248120592_0.jpg" alt="img248120592_0.jpg" style="width:168px;height:63px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Enquiries:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.63%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:70.185%;"></td>
    <td style="width:29.815%;"></td>
   </tr>
   <tr style="height:33.85pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Silence Therapeutics plc</font></p><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Gem Hopkins, VP, Head of IR and Corporate Communications</font></p><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ir@silence-therapeutics.com</font></font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Tel:  +1 (646) 637-3208</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About Silence Therapeutics</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Silence Therapeutics is developing a new generation of medicines by harnessing the body&#x2019;s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence&#x2019;s proprietary mRNAi GOLD&#153; platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence&#x2019;s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. For more information, please visit </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">https://www.silence-therapeutics.com/</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company&#x2019;s clinical and commercial prospects, regulatory approvals of the Company&#x2019;s product candidates, potential partnerships or collaborations or payments under new and existing collaborations, the initiation or completion of the Company&#x2019;s clinical trials and the anticipated timing or outcomes of data reports from the Company&#x2019;s clinical trials. These forward-looking statements are not historical facts but rather are based on the Company's current assumptions, beliefs, expectations, estimates and projections about its industry.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company&#x2019;s most recent Admission Document and its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 15, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>sln-ex99_2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<html>
 <head>
  <title>EX-99</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Exhibit 99.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Silence Therapeutics to Buyback siRNA Complement Assets</font><font style="color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;font-style:italic;min-width:fit-content;">Deal gives Silence exclusive worldwide rights to two siRNA complement assets</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.463%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.463%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(35,64,96,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">28 March 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">LONDON, Silence Therapeutics plc, Nasdaq: SLN (&#x201c;Silence&#x201d; or &#x201c;the Company&#x201d;), an experienced and innovative biotechnology company committed to transforming people&#x2019;s lives by silencing diseases through precision engineered medicines, today announced it will be acquiring back exclusive worldwide rights to two siRNA drug targets under the collaboration agreement with Mallinckrodt Pharmaceuticals for complement-mediated diseases. Under the terms of the agreement, Silence will not make any upfront payment to get the two assets back and Mallinckrodt is eligible to receive future success-based milestones and low single digit royalties on net sales if the projects advance.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#x201c;We want to thank Mallinckrodt for their excellent partnership over the last 3 and a half years,&#x201d; said Craig Tooman, President and CEO of Silence. &#x201c;We are very excited for the opportunity to now have two wholly owned complement assets to add to our portfolio. We continue to see substantial potential for our mRNAi GOLD&#153; platform across multiple therapeutic areas and look forward to generating more clinical data this year in cardiovascular and hematological diseases.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Silence entered into a collaboration agreement with Mallinckrodt in July 2019 to develop and commercialize three siRNA drug targets designed to silence the complement cascade in complement-mediated disorders. Under the new agreement, Silence will gain rights back to two undisclosed preclinical complement targets. SLN501, the C3 targeting program will remain under the collaboration agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Enquiries:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:1.63%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:70.184%;"></td>
    <td style="width:29.816%;"></td>
   </tr>
   <tr style="height:33.85pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.85pt;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Silence Therapeutics plc</font></p><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Gem Hopkins, VP, Head of IR and Corporate Communications</font></p><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">ir@silence-therapeutics.com</font></font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Tel:  +1 (646) 637-3208</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.85pt;text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.06597222222222222in;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">About Silence Therapeutics</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Silence Therapeutics is developing a new generation of medicines by harnessing the body&#x2019;s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence&#x2019;s proprietary mRNAi GOLD&#153; platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence&#x2019;s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Hansoh Pharma, among others. For more information, please visit </font><font><font style="background-color:rgba(0,0,0,0);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">https://www.silence-therapeutics.com/</font></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company&#x2019;s clinical and commercial prospects, regulatory approvals of the Company&#x2019;s product candidates, potential partnerships or collaborations or payments under new and existing collaborations, the initiation or completion of the Company&#x2019;s clinical trials and the anticipated timing or outcomes of data reports from the Company&#x2019;s clinical trials. These forward-looking statements are not historical facts but rather are based on the Company's current assumptions, beliefs, expectations, estimates and projections about its industry.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company&#x2019;s most recent Admission Document and its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March 15, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img248120592_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img248120592_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: /$# 2(  A$! Q$!_\0
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M#\7?^2;:E_O1?^C%K(^!?_(EWG_7\W_H"5K_ !=_Y)MJ7^]%_P"C%K(^!?\
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M N]<U[[;9")E,7VF1_F.,'##%>8_#CQ_:>"(]16YLIKG[68ROE,!MV[NN?\
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MVZ221Q-L9NW%0K7U$-ET'0;RX\Z;2=-FF/.][>-F_,C-:,:11*(HE1%4<(H
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M,&<'C -6=/MC9Z=;6S$,T42H2.A(&*LT4FVPL9>N:=/J5M;I;21QRPW"S R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
